Aegis Sciences Launches New Pharmacogenetic Testing
Nashville, Tennessee (October 14, 2019) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, has launched a new pharmacogenetic (PGx) test that allows for identification of specific gene variants that may impact how behavioral and pain management drugs affect patients. The test results provide clinicians with actionable recommendations for gene-drug interactions to effectively treat patients when initiating or modifying medication therapy.
Aegis will test for the following genes: CYP2C19, CYP2D6 and CYP2C9. These genes are involved in the metabolism of approximately 40% of routinely administered drugs according to a study by Verbeurgt et al. PGx testing looks for changes or variants in these genes that may determine whether a medication could be an effective treatment for a patient or whether a patient is prone to adverse effects.
“As pharmacogenetic testing becomes more routinely used in clinical practice, treatment outcomes will improve for patients who have historically not responded well to psychiatric or neurological therapies,” said Dr. Frank Basile, CEO of Aegis. “Our testing provides clinically relevant information to guide providers in the right direction to find the proper medication, at the proper dose and in less time based on their patients’ unique genetics.”
The PGx test is cost-effective, non-invasive and can be administered during regularly scheduled appointments with healthcare providers. Once the buccal sample is collected, it is sent overnight to Aegis’ BioPharma Laboratory where scientists extract the DNA for genotyping. The report is ready within 10-14 days and is sent via fax, HL7 or web portal. The Aegis Clinical Team is available to assist in result interpretation and provide consultation.
For more information and details, visit https://www.aegislabs.com/our-services/pharmacogenetic-testing/.
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information please visit http://www.aegislabs.com/.